A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

Trial Profile

A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2018

At a glance

  • Drugs Gedivumab (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 24 Apr 2018 Primary endpoint (Time to normalization of respiratory function, defined as the time to cessation of O2 support resulting in a stable SpO2 95% for at least 24 hours) has not been met, according to the results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases.
    • 15 Feb 2018 The study has been discontinued in Italy (End date: 2017-08-07).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top